Madrigal Pharmaceuticals Inc
$ 440.00
0.50%
24 Feb - close price
- Market Cap 9,993,025,000 USD
- Current Price $ 440.00
- High / Low $ 452.30 / 431.14
- Stock P/E N/A
- Book Value 26.39
- EPS -12.86
- Next Earning Report 2026-05-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.16 %
- ROE -0.43 %
- 52 Week High 615.00
- 52 Week Low 265.00
About
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.
Analyst Target Price
$667.57
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-10-29 | 2025-08-05 | 2025-05-05 | 2025-02-26 | 2024-10-31 | 2024-08-07 | 2024-05-07 | 2024-02-28 | 2023-11-06 | 2023-08-08 | 2023-05-09 |
| Reported EPS | -2.57 | -4.9555 | -1.9 | -3.32 | -2.71 | -4.92 | -7.1 | -7.38 | -5.68 | -5.34 | -4.69 | -4.23 |
| Estimated EPS | -0.6039 | -3.36 | -3.63 | -6.28 | -4.1246 | -6.91 | -7.53 | -6.28 | -5.28 | -4.93 | -4.58 | -4.94 |
| Surprise | -1.9661 | -1.5955 | 1.73 | 2.96 | 1.4146 | 1.99 | 0.43 | -1.1 | -0.4 | -0.41 | -0.11 | 0.71 |
| Surprise Percentage | -325.5671% | -47.4851% | 47.6584% | 47.1338% | 34.2967% | 28.7988% | 5.7105% | -17.5159% | -7.5758% | -8.3164% | -2.4017% | 14.3725% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-12 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.8903 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MDGL
2026-02-23 19:29:19
Madrigal Pharmaceuticals (MDGL) is being re-evaluated after Rezdiffra sales neared US$1 billion in 2025, alongside a net loss. Despite recent share price fluctuations, long-term returns remain positive, driven by Rezdiffra's launch. Analysts project the stock is undervalued, with a fair value of $671.07.
2026-02-23 19:05:24
Madrigal Pharmaceuticals (MDGL) is under investor scrutiny after its MASH drug, Rezdiffra, neared US$1 billion in sales for its first full year in 2025, alongside a net loss of US$288.28 million. Despite recent share price fluctuations, long-term returns remain strong. Analysts peg the stock as 35.2% undervalued, with a fair value of $671.07, though potential challenges from rival therapies or pricing pressures could impact future earnings.
2026-02-23 12:36:40
H.C. Wainwright has reiterated a Buy rating on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a $620.00 price target. The firm noted that Rezdiffra, despite recent stock declines and near-term headwinds, has generated significant sales and maintains a high gross profit margin, creating an entirely new treatment category. The addressed patient population has grown substantially, with Rezdiffra still having significant market penetration potential.
2026-02-21 11:12:26
Madrigal Pharmaceuticals' new MASH drug, Rezdiffra, achieved $14.6 million in U.S. sales during its first quarter, significantly surpassing analyst expectations. The company plans to commercialize the drug in Europe independently, anticipating a decision next year. Despite initial concerns about diagnosis and price, Madrigal remains confident in Rezdiffra's potential to become a blockbuster medicine.
2026-02-20 19:43:09
Five analysts have recently provided ratings for Madrigal Pharmaceuticals (NASDAQ: MDGL), with a mix of bullish and somewhat bullish sentiments. The average 12-month price target is $761.60, an increase of 38.66% from the previous average. The company's financial performance shows strong revenue growth of 362.03% but highlights challenges in market capitalization, return on equity, and debt management compared to industry averages.
2026-02-20 16:22:04
Madrigal Pharmaceuticals reported a Q4 2025 loss of $2.57 per share, missing the Zacks Consensus Estimate, primarily due to a significant rise in operating expenses. Despite the earnings miss, the company generated $321.1 million in revenues, beating estimates, driven entirely by sales of its MASH drug Rezdiffra. Madrigal shares fell by 11.1% on the news, reflecting investor disappointment despite strong Rezdiffra sales and ongoing clinical development.
